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Lung cancer i5 the most lethal cancer afflicting men and women. In
the United States, during 2002. o er 1 (9,000 new cases of lung
cancer will have been diagnosed with all hut 14% dying of their
disease in 5 years. The I 54.000 lung cancer deaths anticipated
during 2002 will exceed the combined deaths from breast, prostate.
and colorectal cancer.
There are two major types of lung cancer. The more common.
non-small cell lung cancer \SCLC) account’ for 75%5% of all
lung cancers. ‘ th s mall cell lung cancer SCLC comprising the
rnaority of the remaining I 525f. Besides the histological dif%r
ences, there are distinct molecular, biological, and clinical charac
feristies that set them apart An accurate histological diagnosis is
imperati\ e .since different treatment strategies mar be used fur each
type of lung cancer.
Despite the high prevalence and deadly nature of the disease,
research in lung cancer has lagged behind research in i )ther common
malignancies. There is still a lack of screening and earL detection
methods to identify patients with more curable disease. More
importantly, despite treating the disease at the earliest stages, death
front lung cancer nearly abs avs results Irom the des elopment of
metastases.
Small Cell Lung Cancer
The treatment for SCLC differs from NSCLC. Surgery is rareR
used. and instead the primary treatment modalities are cr totoxic
chemotherapy andor radiotherapy. The treatment and proenosms
are stage dependent. When the disease is confined to one hemitho
rax excluding an ipsilateral maliunant pleural effusion Oimited
staL’c i. the combined Lte of pmatinum—hasecm chemotherapy and
rad otheraps ad an ni stered either concurrently or sequent iall ffer
the greatest. chatice for long-term surviva.i an...d cure. Ovetall. re
sponse rates of 65-Saff with complete response rates of 45-7sa can
he predicted and trattslatc into a median survis :d of I —24 months
with 2-year aml 5-rear ‘urvis a1 rates of an’. and 21% respectts cR
When the disease has spread beyond one hemithorax and/or
associated with a malignant pleural effusion (extensive stage).
treat n cut s tn art ir p att uutn—based c hcmothcrapr Os eral I
somtsc of 5(1-fun v. itO complete response rates ot 2(31% can he
predicted. ss hich translates into a median survival of8-0 months and
a 2.-year survival of<l01/.. in extensi.ve stage SCLC. radiotherapy
is &‘rilr comilnottlv admmnistcrc’d for paliiatomt.
‘I ii ‘ nipt ‘ t. t1c t It t S( ( I i
the last decade. One receittly completed Phase HI trial from Japan
reported superior response and survival rates when a new agent,
ri notecan. is substituted for etoposide in combination ss nIt
cisplat mum in cxtensis e stage SCLC. - A snuilar study ts presently
being conducted in the U.S. with the intent to see if the results can
he duplicated.
Non-Small Cell Lung Cancer
The treatment and prognosis ofNSCLC is dependent on the stage of
the disease at diagnosis. Considered the most curative form of
treatment for \SCI C. surgery is the primarr therap for localized
disease. For Stage I and II NSCLC disease’ that has not spread
beyond hilar lymph nodes, surgical treatment results in a 5—year
survival of 556-’and 3C-35% respectivel.
Patients ss ho are inoperable due to medical reasi ins ir dccli ic
surgery it ia he treated with deli nit ye mad iothcraps hut wt th ri len or
survival rates compared to surgery - Presently there is no consistent
data that show that post—operatis e (adjuvant) radiotherapy and/or
cr tutoxic chemotherapy inipros es survival in localized SCLC.
The treatment for more advanced loco—reciottal disease Stage
lilA), where the tuirtor has spread to the ipsilateral mediasttnal
lymph nodes, usually involves surgery and radiotherapy or the
combination of surgerr . radiotherapy, and cr totoxic ehemutheraps
The 5—rear surs mval rate for Stage I hA disease is 20—25%. When the
disease extends to ins olve major mediastinal structures such as the
trachea, great vessels. supraclavicular lymph nodes, or is associated
Oh a nalienant pleural effusion Stage IIIB i. treat ment is limited
to radiotherapr and/or cv totoxtc chemotherapy. The 5—rear survms al
for this stage of disease is <IOU.
When metastases are present (Stage IV>. the cornerstone of
treatment is cvtotoxtc chemotherapy. The 5—n ear survival for Stage
IV \SCLC is a dismal <I’ 1. Several general statements may he
made rcgardin the role of chemotherapy in the treatment ot ad
vanced NSCLC (Stage IIIB. IV): I) Cytotoxic chemotherapy leads
to symptomatic improvement and longer survival. 21 The use of
platinum—-based icisplatinum. earhoplatin i combination chenmo—
therapy results in superior response and survival rates c)nipare(l to
single drug therapy.3) Combination regimens incorporating newer
drugs such as gemcitahine. paclitaxel. irinotecan. docetaxel, and
vmuorelbine result in superior response and suryts al rates nedman
suns is al y- mnionths: I -y car suns is al approxinlateiy 35% compared
to older regimens. 4> Second-line chemotherapy svith docetaxel
improves survis al compared to supportis e care onlr
Despite mntpnosemnents tn drug theropr . the hencI as it chemni
therapr may has e reached a plateau A recently reported Phase III
trial, comparing, tour commonly used combination chemotherapy
regimens for advanced NSCI -C failed to show a superiorit\ of ann
one regimen. adding cuppoi’m to ‘uch a c nciusion.’’
Newer Approaches to the Treatment of Lung
Cancer
The tm’catmcnt 4 lung cancer i less mhamm ptin’:aI. Modest henefas
aie achics’jhle th present-Jay treammnenm’ foneark lung c.imccrhut
rnuc.h more difficult to ohtan in. advanced disease, With ad.van.ces
i-n molecular biology, genetics. pharmacoIo.,y, pathology, and. hio
technology, the locus ha.- shifted to Jeseloping treatm’mtent’i directed
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certani uniijuc properties of neoplastic cells such as prohteration.
angiogenesis. antiapoptosis. invasion and the ability to metastasize.
The follon inc is a hod s nopsis of three acents that are the farthest
alone ri des clonment. ‘liter aM interfare n ith the function of an
i inportant gron th factor fi mud in normal and neop I atic it ssue: the
epide.rmal f.eowth fac.tor receptor.
The epidermal erosvth factor receptor EGUR is a memberol the
etiruermal arossih factor faniris made up of faur no ir receptor
tr rosine kinase proteins. LEER Erh- I HER ,,HER-rnen ,Erh
2), H ER—3 E.rh-3). and H.E.R.4 I Etwi4[. The. are trans.membra.ne
I TOAd ulvcoprote.ins that mediate. cell nrolitdration. differentiation.
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domain, a rrartsmenibranc region and a c ropiasmic protein knase
domain, Upon lig.and binding, a series of in.t.race.iiular signaling.
pathis aus are triggered. s hich lead to cell roliferation. increased
ancoeene5i . loss of normal apoptos is. and increased. rnelast ad
anitt.j LEER rs frequently os er espressed in N SCLC and rat
in SCLC,
Gefitinib
Ge fitinib ill) I lresajAstra — Zeneea. is a ootertt ECER
tosn akin NC inhibitor TEll 01 th nass ganw uirntvd it m
targets of lung cancer, the most cliniea.l. ex perienee. has been with.
aeft tirit b.
Ta larga Phase li trials have been reported and base shss n hat
this aue.nt indeed has activity in. advanced. N SCLC. Response rates
iaried from M I 9U depending on the trial, More importantly. 35-
patterns. e\penenceu an m rovement in diseaceseelated
smpk ins. \laror toxetnes acre diarrhea and an aenet form rash.
There was no significant rnvei.osuppression or h.air loss.>
Based on these results. two Phase lii trials in NSCLC comparing
cetitrnth in combination is ith chemotherapy to ehcrttotherapv a (1
were. started and 55 er-c ra dlv completed. Disappomnminuls - no
Impros ement in survival has been demonstrated in either trial with
the. addition otgettinh. Clinical trials are continuing with g,efirinih
in conihination svtrh sartor.rs ehernotherap agenr given concur
ends sequentially.
Erlotinib
E.rlotinibr:c)Si7’t.i’am’:es aiGencnteeh is a LEER tvrosine kinase
inhibitor structurally similar to aefiunib. Phase’ I trials round rhi
agent to he well tolerated with. the pri..neipa.l ioxicitiy being diarrhea
and skin rash si.n,siiarto gefitinib. A Phase. 1.1 trial of 56 patients with
N S(’l( wi t U
Phase ..l..[L tn a.is in N SC LC eval uatinn cOot .i nib in eornhina
non with chc.moth rapy have been eom.pleted. hut results are not
a. Another Phase Iii trial evali.iati ni.! cr1 otin ii as nisnnt.heranv
oasis r.raaied sIants a rh au weed NSC I .C is
Cetuximab
Cares i ruth. (( Flrhi t i.1X [malone is a [in man chi inane an no
aissriaL:nubodv thc. hrnds to the LEER is. rh htah affinity. eompa
rabie to the naiu.rai iiga.nd. it causes dowti regulation wi t.l•e. EGER
Si a centring mb 1 md hmqdmc I Ph ra, I owls thy tm...
a t.see.arad to be a I tol er’ate.l with the principal to.x ic ii: ie.s ha i
S I i_
trials are ongoing to evaluate cetuxitnab as first line therapy in
combination with chemotherapy arid as salvage treatment with
ehetiiotherapvA
‘Fire ahos c-mentioned dt’t.rgs are bitt a less of tire mans rareetesi
t[teranies for lttne cancer. [p to now nearis all of them base been
directed at NSCLC. Oth.er targeted th.erapies he.ing e.valuate.d in.
clinical trials include Ras!farnesvi. transf’erase inhilsitons.. pro
.ipopror.ie an-erits. rnbihirmrs sit’ ancanenesis. and aeaiiiem.
Conclusion
Lttna e.anaer- renrainsanlaior health problem. Earl detection
meth ds so tar has epo en t nadeq Ltare and tresitI rient es en a he nr he
N darenosed early remains sahoptirrsa!. identification of
tiumoer otn.ovel targets of lung cancer has le.d to the davelopmen.t
oftarne.ted therapies with fb.wer side effe.ers and in se.leete.d clinical
sti.tatotis euual alt icac\ svhen corsrt’ared to eonventonat eheirru
therapy It is liked that s tb the development at such aaermt’. that we
will s.e.c a chan.e. in the sreatme.nt panadig.:tn i.Er I ur.g cartcer. Many
quest ions remain unanswered in terms of the. exact role these newer
ireatirtents a ill play mu lumg e,uieermanaeenmeni con_ertest atruri
by all disciplines immvols ad in the studs and treaevenr. of this diseasy
will be needed to anssve.r the.sc ques.Uonic J?ec a-ch Brin.ps’ Hope
Eon tno:re infot.mation. visit the Cancer Research Center’s website at
sssva.creh.ore oreall use Cancer iritormaron.Ser.ee of Hanami at
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